Core Insights - The company, 泰恩康, reported a decline in revenue and net profit for the first half of 2025, with revenue at 347 million yuan, down 12.23% year-on-year, and net profit at 37.08 million yuan, down 56.75% [1] Revenue Breakdown - The core segment of gastrointestinal medications saw a revenue increase of 103.39 million yuan, reflecting a year-on-year growth of 11.04% [1] - Revenue from ophthalmic medications was 79.38 million yuan, showing a decrease of 9.02% year-on-year [1] - The revenue from sexual health medications dropped significantly to 66.74 million yuan, a decline of 48.75% year-on-year, attributed to increased competition and a rise in the number of competing products [1]

Core Viewpoint - The company, 泰恩康 (301263.SZ), reported a decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved an operating revenue of 347 million yuan, representing a year-on-year decrease of 12.23% [1] - The net profit attributable to shareholders of the listed company was 37.08 million yuan, down 56.75% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 36.88 million yuan, reflecting a year-on-year decline of 56.30% [1] - The basic earnings per share were reported at 0.09 yuan [1]

Core Insights - The company reported a total revenue of 347 million yuan for the first half of 2025, representing a year-on-year decline of 12.23% [1] - The net profit attributable to shareholders was 37.08 million yuan, down 56.75% year-on-year, with basic earnings per share at 0.09 yuan [1] - The core business segment of gastrointestinal drugs saw revenue growth, while sales in sexual health and ophthalmic drugs declined [1] R&D and Product Development - R&D investment reached 48.64 million yuan in the first half of 2025, with significant progress in innovative drug development and key product industrialization [1] - The II phase clinical trial for CKBA ointment targeting vitiligo has completed data organization and unblinding, showing positive efficacy and safety in non-segmental vitiligo patients [1] - The application for breakthrough therapy status for CKBA has been submitted to CDE, with preparations for the III phase clinical trial underway [1] Product Pipeline and Market Strategy - The application for the II/III phase seamless adaptive clinical trial of CKBA cream for rosacea has been officially accepted, confirming its development potential in the autoimmune field [2] - The domestic production registration application for Hewei Zhengchang Wan has been accepted, with production line modifications completed for rapid commercialization upon approval [2] - New gastrointestinal products, including Compound Sodium Sulfate Tablets, have completed clinical research and received market acceptance, enhancing the product matrix [2] Strategic Focus - The year 2025 is identified as a critical year for the company's dual strategy of innovation and brand promotion [3] - Increased investment in brand promotion aims to establish a solid foundation for the commercialization of core potential products like Hewei Zhengchang Wan and others [3] - The company targets significant sales growth in its three core segments: gastrointestinal, ophthalmic, and sexual health over the next 3-5 years [3]

Group 1 - The company, 泰恩康 (301263.SZ), reported a revenue of 347 million yuan for the first half of 2025, representing a year-on-year decrease of 12.23% [1] - The net profit attributable to shareholders of the listed company was 37.08 million yuan, down 56.75% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 36.88 million yuan, reflecting a year-on-year decline of 56.30% [1] - The basic earnings per share were reported at 0.09 yuan [1]

Core Viewpoint - The company, 泰恩康, announced the convening of its fifth board meeting to review the 2025 semi-annual report and its summary, indicating ongoing corporate governance and financial transparency [1]. Financial Performance - For the year 2024, 泰恩康's revenue composition is as follows: pharmaceutical agency accounts for 61.1%, pharmaceutical manufacturing for 37.28%, pharmaceutical technology services for 1.51%, and other businesses for 0.12% [1]. - The current market capitalization of 泰恩康 is 15.4 billion yuan [1].

Core Viewpoint - The company TianKang reported a decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [2]. Financial Performance - The company's operating revenue for the first half of 2025 was approximately 347 million yuan, a year-on-year decrease of 12.23% [2]. - The net profit attributable to shareholders was around 37.08 million yuan, reflecting a significant year-on-year decline of 56.75% [2]. - Basic earnings per share were reported at 0.09 yuan, which is a decrease of 55% compared to the previous year [2].

广东泰恩康医药股份有限公司投资者关系管理制度 广东泰恩康医药股份有限公司 投资者关系管理制度 第一章 总 则 第 1 页 共 13 页 广东泰恩康医药股份有限公司投资者关系管理制度 和反映公司的实际状况，不得出现以下情形： （一）透露或通过非法定方式发布尚未公开披露的重大信息； 第一条 为进一步加强广东泰恩康医药股份有限公司（以下简称"公司"） 与投资者和潜在投资者（以下统称"投资者"）之间的沟通，促进投资者对公 司的了解，进一步完善公司法人治理结构，实现公司整体利益和股东利益最 大化，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》（以下简称"《证券法》"）、《深圳证券交易所上市公司自律监 管指引第 2 号—创业板上市公司规范运作》（以下简称"《自律监管指引第 2 号》"）等有关法律、法规、规范性文件及《广东泰恩康医药股份有限公司章 程》（以下简称"《公司章程》"）的规定，结合公司实际情况，特制订本制度。 第二条 投资者关系管理是指公司通过各种方式的投资者关系活动，加 强与投资者和潜在投资者之间的沟通，增进投资者对公司了解的管理行为。 第三条 公司投资者关系管理工作应严格遵 ...

广东泰恩康医药股份有限公司独立董事工作细则 广东泰恩康医药股份有限公司 独立董事工作细则 第一章 总则 第一条 为促进广东泰恩康医药股份有限公司（以下简称"公司"）的规范 运作，规范独立董事的行为，维护公司整体利益，保障全体股东特别是中小股东 的合法权益不受损害，根据《中华人民共和国公司法》（以下简称《公司法》）、 《上市公司独立董事管理办法》（以下简称《独立董事管理办法》）、《上市公司治 理准则》（以下简称《治理准则》）、《深圳证券交易所创业板股票上市规则》（以 下简称《上市规则》）、《深圳证券交易所上市公司自律监管指引第 2 号—创业板 上市公司规范运作》（以下简称《自律监管指引第 2 号》）等法律、法规、其他规 范性文件以及《广东泰恩康医药股份有限公司章程》（以下简称《公司章程》）的 有关规定，结合公司的实际情况，特制订本制度。 第二条 释义 若未作特殊说明，下列用语在本制度中具有以下含义： 独立董事：是指不在公司担任除董事外的其他职务，并与公司及其主要股东、 实际控制人不存在直接或者间接利害关系，或者其他可能影响其进行独立客观判 断关系的董事。 中国证监会：是指中国证券监督管理委员会。 证券交易所：是 ...

广东泰恩康医药股份有限公司董事会战略委员会工作细则 第二章 人员组成 第一章 总 则 第一条 为了完善广东泰恩康医药股份有限公司（以下简称"公司"） 治理结构，增强公司核心竞争力，确定公司发展规划，健全投资决策程序， 加强决策科学性，提高重大投资决策的效益和决策的质量，根据《中华人民 共和国公司法》、《上市公司治理准则》、《深圳证券交易所创业板股票上市规 则》、《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范 运作》等有关法律、法规、规范性文件及《广东泰恩康医药股份有限公司章 程》（以下简称"《公司章程》"）的规定，公司特设立董事会战略委员会（以 下简称"战略委员会"），并制订本细则。 第二条 战略委员会是董事会按照《公司章程》设立的专门工作机构， 主要负责对公司中长期发展战略和重大战略投资决策进行研究并提出建议。 第三条 战略委员会成员由 3 名董事组成。 第四条 战略委员会由下列成员组成：1、董事长；2、董事会选举产生 的其他董事。 第五条 战略委员会设主任委员（召集人）一名，由公司董事长担任。 第六条 战略委员会任期与董事会任期一致，委员任期届满，连选可以 连任。期间如有委员不再担任公 ...

广东泰恩康医药股份有限公司内部控制制度 第一章 总则 第一条 为了加强广东泰恩康医药股份有限公司（以下简称"公司"或"本 公司"）内部控制制度建设，强化企业管理，健全自我约束机制，促进现代企 业制度的建设和完善，保障公司经营战略目标的实现，根据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国会计法》(以下简 称"《会计法》")、《企业内部控制基本规范》、《深圳证券交易所上市公司 自律监管指引第2号—创业板上市公司规范运作》（以下简称"《自律监管指 引第2号》"）等其他相关的法律法规、其他规范性文件以及《广东泰恩康医 药股份有限公司章程》（以下简称"《公司章程》"），制订本制度。 第二条 内部控制是指公司董事会、审计委员会、高级管理人员及所有员 工共同实施的，为了保证各项经济活动的效率和效果，确保财务报告的可靠 性，保护资产的安全、完整，防范、规避经营风险，防止欺诈和舞弊，确保 有关法律法规和规章制度的贯彻执行等而制定和实施的一系列具有控制职能 的业务操作程序、管理方法与控制措施的总称。 内部控制中公司各个层级应承担的职责如下： （一）董事会：对内部控制的建立健全和有效实施负责，全面负责公 ...